D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
Heidi Hagen, a director at Vericel Corp (NASDAQ:VCEL), sold 9,000 shares of the company’s common stock on March 3, according to a recent SEC filing. The shares were sold at an average price of $49.53 each, amounting to a total transaction value of $445,770. This sale was executed under an automatic trading plan established in November 2024. The transaction comes as Vericel, currently valued at $2.58 billion, demonstrates strong revenue growth of 20.1% over the last twelve months. According to InvestingPro analysis, the company maintains robust liquidity with a current ratio of 4.23.
In a related transaction on the same day, Hagen exercised stock options to acquire 9,000 shares at a price of $3.74 per share, totaling $33,660. Following these transactions, Hagen holds 28,650 shares of Vericel’s common stock. InvestingPro identifies several key insights about Vericel, including its volatile stock movements and high earnings multiples. Subscribers can access 12 additional ProTips and a comprehensive Pro Research Report for deeper analysis.
In other recent news, Vericel Corporation reported robust financial results for the fourth quarter of 2024, achieving a 20% year-over-year increase in total revenue to $237.2 million and a net income of $10.4 million, a significant improvement from a loss of $3.2 million the previous year. The company also reported a record Q4 gross margin of 78%, contributing to a full-year gross margin of 73%. Despite the strong performance, Truist Securities adjusted its price target for Vericel to $61 from $67, maintaining a Buy rating, citing Vericel’s potential for growth with new product launches like MACI Arthro. Analysts at Truist believe the company’s full-year 2025 guidance is conservative, anticipating increased sales from product launches. Vericel’s strategic initiatives, including the expansion of its MACI and burn care franchises, have positioned it well for sustained growth, with projections for 2025 revenue growth of 20-23%. The company expects MACI revenue to grow in the low 20% range, while NexoBrid and Epicel revenues are anticipated to see high single-digit growth. Vericel’s management highlighted strong early indicators for MACI Arthro adoption and plans for international market entry in 2027-2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.